Kashi Toxicology offers genetic testing for pain management biomarkers to so you can maximize the effectiveness of analgesic drug use. Managing chronic pain is a challenge for healthcare providers because of each patient’s unique tolerance to pain and differing reactions to prescribed medications.1 Unpleasant opioid side effects such as nausea, vomiting, constipation and sedation, are common with pain management medication. These side effects can lead to work absences, poor work performance, the risk of job loss, and a diminished quality of life.2,3 An individual’s genetic makeup may predispose them to adverse effects of pain and reduced efficacy of medications.1 Kashi Toxicology’s Pharmacogenetics testing, designed to provide genetics-based information on a patient’s DNA, can help health providers mitigate adverse drug reactions.
Gene Tests Included in the Pain Management Panel
| GENE MARKER | EFFECT ON PAIN MANAGEMENT |
|---|---|
| CYP2D6 | Key role in the metabolism of opioids including codeine, tramadol, and oxycodone1,7 |
| CYP2C19 | Impacts dosage requirements for tricyclic antidepressants8 |
| CYP2C9 | Crucial to the breakdown of NSAIDS including diclofenac, naproxen, and ibuprofen6 |
| CYP3A4/5 | Key role in the metabolism of opioids including fentanyl and methadone5,9 |
| COMT | Affects morphine dosage requirements and perceptions of pain10 |
